Shares of Biocon, a pharmaceutical company, rose by as much as 2% on Tuesday, 25 February, after Biocon Biologics, a fully integrated global biosimilars company and Biocon subsidiary, announced that Yesintek (ustekinumab-kfce) is now available to patients in the United States.  

Among the first biosimilars to enter the US market, Yesintek was a competitor of Stelara (Ustekinumab).

Shreehas Tambe, CEO and managing director of Biocon Biologics, said: “The launch of Yesintek marks a significant step in our commitment to improving the lives of patients with inflammatory conditions and expanding access to high-quality biosimilars. It also represents our first product launch in the United States since becoming a fully integrated global biosimilars organisation. We are excited to be among the first companies to introduce a high-quality, affordable biosimilar Ustekinumab to this patient population.” 

Yesintek can be used to treat a variety of chronic autoimmune diseases, including psoriatic arthritis, ulcerative colitis, plaque psoriasis, and Crohn’s disease. It provides patients with access to more affordable treatments for certain conditions. 

Yesintek will be available in the same formulations as Stelara: 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.

In addition to commercial payor coverage, Yesintek will offer a wide range of patient assistance services, such as benefits verification and copay assistance. Patients who fit the program’s eligibility criteria could pay as little as $0.

A monoclonal antibody called Yesintek targets the signalling pathways mediated by IL-12 and IL-23, which are connected to immune-related illnesses.

Additionally, clinical trials have shown that Yesintek is a biosimilar of Stelara, having identical immunogenicity, safety, effectiveness, and pharmacokinetic properties. 

Earlier in December 2024, the US Food and Drug Administration (USFDA) approved Yesintek.
 
The company is expanding its manufacturing capacity globally with the recent acquisition of an oral solid dosage facility in the US and a biologics manufacturing plant through Syngene. 
 
At 11:40 am, the shares of Biocon were trading 0.92% higher at Rs 323.80 on NSE.

Curious About Biocon? Ask the Analyst.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!